The PIONEER program was designed to test oral semaglutide in patients at different stages across diabetes natural history (mean diabetes duration, 3.5–15 years) and background treatments (monotherapy, added to 1 or 2 oral glucose-lowering agents, or added to insulin). This evidence concerns the gene INS and diabetes mellitus.